According to the Zhitong Finance App, Peijia Medical-B (09996) announced that the group's revenue for the first half of 2026 was approximately RMB 415 million to RMB 435 million, an increase of about 17.4% to 23.1% over the previous year.
The Group's steady revenue growth is mainly due to: (i) the continuous expansion of the transcatheter valve treatment business, mainly driven by the successful commercialization of new indicated products, and the Group's mature transcatheter aortic valve replacement (TAVR) commercialization capabilities, enabling the Group to seize new market opportunities for approved indications for aortic valve reflux (AR); and (ii) the continued growth of the Group's neurological intervention business driven by continued market penetration of its self-developed products and expansion of its product portfolio through strategic cooperation.
As far as the transcatheter valve treatment business is concerned, the Group continues to strengthen its leading position in the TAVR market in China. As of June 30, 2026, the Group's TAVR product portfolio has expanded hospital coverage to more than 850 hospitals in Greater China, an increase of approximately 70 hospitals over December 31, 2025. During the reporting period, the total number of TAVR implants (including the implantation of aortic stenosis (AS) and AR indicated products) reached about 2,830 units, a significant increase of about 36.5% over the six months ended June 30, 2025 based on implantation volume.
The growth in the transcatheter valve therapy business has mainly benefited from the successful commercialization of the Taurustrio® Transcatheter Aortic Valve System, which is the Group's TAVR system specially designed to treat AR. With the Group's extensive experience in commercializing TAVR in the AS market over many years and the established commercial infrastructure, Taurustrio® was quickly adopted by the market after launch. As a novel solution to unmet clinical needs in AR treatment, Taurustrio® has accelerated clinical application promotion with its product design advantages, safety performance and standardized surgical procedures, and has been widely recognized by the market. During the reporting period, TauruRIO® was implanted in more than 660 cases in mainland China, showing good clinical acceptance and potential for commercialization. At the same time, with the differentiated performance of the Group's 3D adjustable curved TAVR system, TaurusMax®, the Group's AS adaptation product portfolio continues to grow in an increasingly competitive market environment.
As far as the neurointervention business is concerned, benefiting from a model combining independent innovation and strategic cooperation, the Group continues to expand its product portfolio and enhance its market competitiveness. The Group's own products (including Syphonet® embolation stents, Fastunnel® conveying balloon expansion catheter, and DCWire® microguide wire) continue to gain market recognition due to their differentiated design and excellent performance, driving continued market penetration and revenue growth. At the same time, through strategic cooperation, the Group further expanded its neurological intervention business and launched products in collaboration with strategic partners, including YonFlow® blood-flow guided mesh stents and Qida® disposable neural catheter sheaths, which expanded the scale of commercialization and contributed to additional revenue growth during the reporting period.